Predicting malignancy in solid thyroid nodules with no or punctate-linear enhancement on contrast-enhanced ultrasound: a retrospective analysis Authors: Ruijun Kang, Jiajia Tang, Yichan Zhang, Jiaojiao Ma, Bo Zhang Published: 2026 ABSTRACT AbstractBackgroundThe 2020 Chinese Thyroid Imaging Reporting and Data System (C-TIRADS) regards no or scant punctate-linear enhancement on contrast-enhanced ultrasound (CEUS) as a benign feature in thyroid nodules. However, emerging evidence suggests that some malignant nodules may also exhibit this enhancement pattern. Few systematic studies focusing on the differential diagnosis of such nodules have been conducted. Therefore, this study aimed to identify the ultrasound (US) and CEUS characteristics of malignant solid thyroid nodules with no or punctate-linear enhancement and to evaluate their diagnostic value in distinguishing between benign and malignant lesions.MethodsA retrospective analysis was conducted on clinical and imaging data from 107 patients with 108 pathologically confirmed solid thyroid nodules exhibiting no or punctate-linear enhancement on CEUS, with 73 benign and 35 malignant nodules ultimately being analyzed. Punctate-linear enhancement was further categorized as internal or peripheral based on the location of microbubbles. The basic characteristics, as well as US and CEUS characteristics, were compared between benign and malignant nodules. Multivariate logistic regression analysis was performed to identify independent predictors for malignancy, with odds ratio (OR) and 95% confidence interval (CI) calculated. Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic performance, and the area under the curve was calculated with 95% CI, as well as the sensitivity and specificity.ResultsSignificant differences were observed between the two groups in terms of location, margin, orientation, echogenic foci, enhancement pattern, and enhancement margin (all P<0.05). Multivariate analysis identified that the independent predictors of malignancy were isthmic location (OR =28.288; 95% CI: 4.515–177.250, P<0.001), ill-defined/irregular margin (OR =10.221; 95% CI: 1.929–54.156, P=0.006), microcalcifications (OR =6.516; 95% CI: 1.392–30.497, P=0.017), and peripheral punctate-linear enhancement (OR =15.587, 95% CI: 2.932–82.855, P=0.001), which yielded areas under the curve of 0.702 (95% CI: 0.587–0.816), 0.729 (95% CI: 0.628–0.830), 0.687 (95% CI: 0.572–0.803), and 0.765 (95% CI: 0.674–0.856), respectively; meanwhile the combined model achieved an area under the curve of 0.944 (95% CI: 0.905–0.984), with a sensitivity of 0.943 and a specificity of 0.836.ConclusionsSolid thyroid nodules with no or punctate-linear enhancement on CEUS are not exclusively benign. The combination of isthmic location, ill-defined/irregular margin, microcalcifications, and peripheral punctate-linear enhancement may accurately indicate malignancy. These findings may assist in identifying malignant lesions and reducing unnecessary invasive procedures for benign nodules.Keywords: Thyroid nodule, contrast-enhanced ultrasound (CEUS), Thyroid Imaging Reporting and Data System, diagnostic differentiation, enhancement pattern Introduction The global incidence of thyroid nodules has been increasing in recent years, with a prevalence of approximately 25% in the general population (1). Since the malignancy rate is only 10–15% (2), the primary goal of thyroid nodule assessment is to identify malignant lesions (3). Ultrasound (US) is considered one of the most important methods for thyroid nodule evaluation (4). According to the 2020 Chinese Thyroid Imaging Reporting and Data System (C-TIRADS) (5), solid thyroid nodules are categorized as C-TIRADS 4 or higher and have a malignancy risk ranging from 2% to over 90%. However, due to the overlap of US characteristics between benign and malignant nodules, identifying malignancy with US alone may be challenging, and additional diagnostic modalities may be required for accurate diagnosis (4). Contrast-enhanced ultrasound (CEUS) can reflect the microvascular perfusion of nodules and provide a greater degree of diagnostic information than conventional US (6,7). Some research (8-10) suggests that no enhancement or punctate-linear enhancement is a reliable indicator for benign lesions. The C-TIRADS guidelines (5) recommend that some solid nodules of category 4 or 5 with no or scant punctate-linear enhancement in the whole or most of the regions of the nodules on CEUS can be downgraded to category 2 or 3. However, some studies (11,12) have reported that malignant nodules may also exhibit this specific enhancement pattern on CEUS, which may cause diagnostic confusion in clinical practice. Notably, the majority of studies on thyroid CEUS have focused primarily on broad comparisons of enhancement patterns, and there is a lack of targeted research on the subgroup of nodules with no or punctate-linear enhancement. Furthermore, the C-TIRADS guidelines (5) only define scant punctate-linear enhancement based on the extent of enhancement, without specifying the location of enhancement. To address these critical issues, we first classified the punctate-linear enhancement into internal and peripheral subtypes according to the location of microbubbles and evaluated the US and CEUS features of nodules with no or punctate-linear enhancement. The purpose of this study was to identify US and CEUS characteristics associated with malignancy in this specific subgroup and to assess their value in differential diagnosis. We present this article in accordance with the STARD reporting checklist (available at https://qims.amegroups.com/article/view/10.21037/qims-2025-1-2767/rc). Methods This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments, and was approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2019-103-K71). The requirement for informed consent was waived due to the retrospective nature of the analysis. Patients From January 2022 to October 2025, the data from patients with solid thyroid nodules who underwent both US and CEUS examinations before fine-needle aspiration (FNA) or surgery in China–Japan Friendship Hospital were collected. All patients in this study were asymptomatic, and nodules were identified during routine US examinations. The inclusion criteria were as follows: (I) no enhancement or punctate-linear enhancement on CEUS; (II) pathological results obtained by FNA or surgery. The exclusion criteria were as follows: (I) incomplete or missing imaging data; (II) nodules classified as Bethesda I, III, IV, or V based on The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) (13); (III) a history of ablation or FNA (Figure 1). Flowchart of patient selection and study design. CEUS, contrast-enhanced ultrasound; FNA, fine-needle aspiration; US, ultrasound. US and CEUS examinations US and CEUS examinations were performed with US diagnostic equipment, including the ACUSON Sequoia (Siemens Healthineers, Erlangen, Germany), and EPIQ Elite, EPIQ 7, and EPIQ 7C (Philips Medical Systems, Bothell, WA, USA). Line array probes were used with frequencies from 4 MHz to 18 MHz. CEUS was performed after detection of thyroid nodules on US, with a 0.6–2.0 mL intravenous bolus injection of microbubble contrast agent (SonoVue, Bracco, Milan, Italy), and the timer on the system was initiated simultaneously. The CEUS dynamic videos were continuously recorded for at least 90 seconds. US and CEUS image analysis The US characteristics of each nodule were evaluated according to size (maximum diameter), location (left lobe, right lobe, or isthmus), echogenicity (markedly hypoechoic, hypoechoic, isoechoic, or hyperechoic), margin (circumscribed or ill-defined/irregular), orientation (vertical or horizontal), echogenic foci (none, microcalcifications, or macrocalcifications), posterior features (none, enhancement, or shadowing), and vascular pattern (avascularity, peripheral vascularity, mainly peripheral vascularity, mainly central vascularity, or mixed vascularity). All thyroid nodules were classified as per the C-TIRADS (5). The CEUS characteristics of each nodule were based on the enhancement pattern and the enhancement margin. The enhancement pattern was categorized into two types: no enhancement and punctate-linear enhancement. According to C-TIRADS (5), no enhancement was defined as the absence of microbubbles in the whole or most of the regions of the nodules, and punctate-linear enhancement was defined as a distribution of microbubbles in a punctate and/or linear pattern throughout the entire or most areas of the nodules. Based on the location of microbubble distribution, punctate-linear enhancement was further classified into two subtypes: internal punctate-linear enhancement and peripheral punctate-linear enhancement. Enhancement observed within 0.15 cm of the nodule margin was defined as peripheral punctate-linear enhancement. For nodules with a maximum diameter smaller than 0.5 cm, the enhancement thickness was further restricted to no more than one-fifth of the maximum diameter. In contrast, enhancement located in the central area beyond this peripheral zone was defined as internal punctate-linear enhancement. For nodules in which both patterns coexisted, the predominant pattern was determined according to the area with the highest density of microbubble distribution. The enhancement margin was classified as well-defined and ill-defined in comparison with the surrounding enhanced thyroid parenchyma. The US and CEUS images were reviewed independently by two radiologists with at least 5 years of experience in US and CEUS diagnosis. Before analysis, they were blinded to the clinical information of patients and the pathological results of thyroid nodules. If disagreements were encountered, a third reviewer with 10-year experience in US and CEUS diagnosis would analyze the images and determine the final results. Pathological analysis All pathological diagnoses were determined by experienced pathologists who were blinded to patients’ clinical information and imaging findings. Follow-up US After US and CEUS examinations, FNA or surgical treatment was performed for all solid nodules. For patients who underwent FNA, follow-up US data were retrospectively collected and reviewed. Reference standard For malignant nodules, the pathologic results after surgery or FNA results classified as Bethesda VI were regarded as the reference standard. For benign nodules, FNA results classified as Bethesda II combined with a minimum follow-up duration of 6 months and histopathologic results after surgery were used as the reference standard. The FNA results were based on TBSRTC (13). Statistical analysis Continuous variables are presented as the median and interquartile range, while categorical variables are presented as frequencies and percentages. Group comparisons were performed via the Mann-Whitney U test for continuous variables and via the Chi-square (ꭓ2) test or Fisher’s exact test for categorical variables. Univariate analysis was conducted to identify variables associated with malignancy. Variables exhibiting significant associations in the univariate analysis were then included in the multivariate logistic regression analysis to identify independent risk factors for malignancy. The diagnostic performance of each independent risk factor and the combined model was evaluated via the area under the receiver operating characteristic (ROC) curve (AUC). Comparisons of AUCs with 95% confidence intervals (CIs) were conducted via the DeLong test. Interobserver agreement in the analysis of imaging characteristics of thyroid nodules was assessed with the Cohen’s kappa coefficient. All analyses were conducted with SPSS 25.0 (IBM Corporation, Armonk, NY, USA) and MedCalc 23.0.2 (MedCalc Software, Ostend, Belgium). Differences were considered statistically significant at P<0.05. Results Baseline characteristics Ultimately, 107 patients (81 females and 26 males; median age, 47 years; age range, 25–79 years), comprising 108 solid thyroid nodules (73 benign nodules and 35 malignant nodules), were enrolled in this study. One patient contributed two nodules (one in each lobe). The maximum diameter of nodules ranged from 0.3 to 2.2 cm (median: 0.9 cm). Among all the nodules, 27 were diagnosed as malignant by postoperative pathology, all of which were papillary thyroid carcinoma; the remaining 81 nodules were pathologically confirmed via FNA, with 73 and 8 being Bethesda II and Bethesda VI, respectively. The age of patients with malignant nodules was significantly lower than that of those with benign nodules (P<0.001). The sex of patients and the maximum diameter of nodules did not differ significantly between the benign and malignant groups (P>0.05). Table 1 shows the baseline characteristics of the patients included in this study. Table 1Baseline characteristics of the study patientsCharacteristicsBenignMalignantP valueNumber of patients7235Number of nodules7335Sex0.477 Male16 (21.9)10 (28.6) Female56 (78.1)25 (71.4)Age (years)60 [43–66]35 [32–43]<0.001*Maximum diameter (cm)0.9 [0.7–1.1]0.8 [0.7–1.1]0.186Data are presented as median [interquartile range] or number (percentage) unless otherwise indicated. *, P<0.05. Baseline characteristics of the study patients Data are presented as median [interquartile range] or number (percentage) unless otherwise indicated. *, P<0.05. US and CEUS features The US characteristics of 108 solid thyroid nodules are presented in Table 2. Significant differences between the benign and malignant groups were observed in terms of location, margin, orientation, and echogenic foci (P<0.05). Malignant nodules were more frequently associated with ill-defined/irregular margins, vertical orientation, and microcalcifications. Nearly half of the malignant nodules were located in the isthmus. There were no significant differences in echogenicity, posterior features, or vascular pattern between the two groups (P>0.05). Compared with benign nodules, malignant nodules were often classified as C-TIRADS 4C or 5 (68.6% vs. 19.2%; P<0.001). There was substantial to almost perfect agreement between the two radiologists in the assessment of US characteristics, with κ values for interobserver agreement ranging from 0.646 to 0.814. Table 2Comparison of US characteristics in solid thyroid nodules with no or punctate-linear enhancement on CEUSCharacteristicsBenign (n=73)Malignant (n=35)P valueLocation<0.001* Left lobe36 (49.3)8 (22.8) Right lobe31 (42.5)10 (28.6) Isthmus 6 (8.2)17 (48.6)Echogenicity0.051 Hypoechoic57 (78.1)33 (94.3) Markedly hypoechoic16 (21.9)2 (5.7)Margin<0.001* Circumscribed48 (65.8)7 (20.0) Ill-defined/irregular25 (34.2)28 (80.0)Orientation0.013* Vertical23 (31.5)20 (57.1) Horizontal50 (68.5)15 (42.9)Echogenic foci<0.001* None37 (50.7)15 (42.9) Microcalcifications6 (8.2)16 (45.7) Macrocalcifications30 (41.1)4 (11.4)Posterior features0.118 None62 (84.9)34 (97.1) Shadowing11 (15.1)1 (2.9)Vascular pattern0.828 Avascularity23 (31.5)12 (34.3) Peripheral vascularity50 (68.5)23 (65.7)C-TIRADS<0.001* 4A30 (41.1)3 (8.6) 4B29 (39.7)8 (22.8) 4C14 (19.2)23 (65.7) 501 (2.9)Data are presented as number (percentage). *, P<0.05. C-TIRADS, Chinese Thyroid Imaging Reporting and Data System; CEUS, contrast-enhanced ultrasound; US, ultrasound. Comparison of US characteristics in solid thyroid nodules with no or punctate-linear enhancement on CEUS Data are presented as number (percentage). *, P<0.05. C-TIRADS, Chinese Thyroid Imaging Reporting and Data System; CEUS, contrast-enhanced ultrasound; US, ultrasound. Table 3 summarizes the CEUS features of solid thyroid nodules included in this study. There were significant differences in the enhancement pattern and enhancement margin (P<0.05). Peripheral punctate-linear enhancement was more commonly observed in malignant nodules (Figure 2). In contrast, internal punctate-linear enhancement was more commonly observed in benign lesions than in malignant lesions (Figure 3). No enhancement was found only in benign nodules (Figure 4). Over half of the malignant nodules exhibited an ill-defined enhancement margin (Figure 5). The κ value for CEUS characteristics was 0.795 for the enhancement pattern and 0.739 for the enhancement margin. Table 3Comparison of CEUS characteristics in solid thyroid nodules with no or punctate-linear enhancement on CEUSCharacteristicsBenign (n=73)Malignant (n=35)P valueEnhancement pattern<0.001* No enhancement17 (23.2)0 Internal punctate-linear enhancement28 (38.4)3 (8.6) Peripheral punctate-linear enhancement28 (38.4)32 (91.4)Enhancement margin0.002* Well-defined56 (76.7)16 (45.7) Ill-defined17 (23.3)19 (54.3)Data are presented as number (percentage). *, P<0.05. CEUS, contrast-enhanced ultrasound. Comparison of CEUS characteristics in solid thyroid nodules with no or punctate-linear enhancement on CEUS Data are presented as number (percentage). *, P<0.05. CEUS, contrast-enhanced ultrasound. A 32-year-old female with papillary thyroid carcinoma confirmed by post-surgical pathological results. (A) US showed a solid nodule in the isthmus that was hypoechoic with an ill-defined margin and microcalcifications (C-TIRADS 4C). (B) CEUS showed a punctate-linear enhancement pattern in the peripheral region of the nodule (red arrow). C-TIRADS, Chinese Thyroid Imaging Reporting and Data System; CEUS, contrast-enhanced ultrasound; US, ultrasound. A 60-year-old female with a benign nodule confirmed by FNA. (A) US showed a solid nodule in the right lobe that was hypoechoic with an ill-defined margin (C-TIRADS 4B). (B) CEUS showed a punctate-linear enhancement pattern in the internal region of the nodule. C-TIRADS, Chinese Thyroid Imaging Reporting and Data System; CEUS, contrast-enhanced ultrasound; FNA, fine-needle aspiration; US, ultrasound. A 53-year-old female with a benign nodule confirmed by FNA. (A) US showed a solid nodule in the left lobe that was hypoechoic with a circumscribed margin (C-TIRADS 4A). (B) CEUS showed no microbubbles entering the nodule (no enhancement). C-TIRADS, Chinese Thyroid Imaging Reporting and Data System; CEUS, contrast-enhanced ultrasound; FNA, fine-needle aspiration; US, ultrasound. A 49-year-old female with papillary thyroid carcinoma confirmed by post-surgical pathological results. (A) US showed a solid nodule in the left lobe that was hypoechoic with an ill-defined margin, vertical orientation, and microcalcifications (C-TIRADS 4C). (B) CEUS showed an ill-defined enhancement margin compared with the surrounding enhanced thyroid parenchyma (red arrows). C-TIRADS, Chinese Thyroid Imaging Reporting and Data System; CEUS, contrast-enhanced ultrasound; US, ultrasound. Multivariate logistic regression analysis Multivariate logistic regression analysis was performed and included all US and CEUS variables that reached statistical significance (P<0.05). As shown in Table 4, the independent predictors of malignancy were isthmic location [odds ratio (OR) =28.288; 95% CI: 4.515–177.250; P<0.001], ill-defined/irregular margin (OR =10.221; 95% CI: 1.929–54.156; P=0.006), microcalcifications (OR =6.516; 95% CI: 1.392–30.497; P=0.017), and peripheral punctate-linear enhancement (OR =15.587; 95% CI: 2.932–82.855; P=0.001). Table 4Multivariate logistic regression analysis of factors associated with malignancy in solid thyroid nodules with no or punctate-linear enhancement on CEUSUS and CEUS characteristicsBSEP valueOR95% CIIsthmic location3.3420.936<0.001*28.2884.515–177.250Ill-defined/irregular margin2.3240.8510.006*10.2211.929–54.156Vertical orientation1.1470.7740.1383.1470.691–14.341Microcalcifications1.8740.7870.017*6.5161.392–30.497Peripheral punctate-linear enhancement2.7460.8520.001*15.5872.932–82.855Ill-defined enhancement margin−0.3530.7130.6200.7030.174–2.840*, P<0.05. CEUS, contrast-enhanced ultrasound; CI, confidence interval; OR, odds ratio; SE, standard error; US, ultrasound. Multivariate logistic regression analysis of factors associated with malignancy in solid thyroid nodules with no or punctate-linear enhancement on CEUS *, P<0.05. CEUS, contrast-enhanced ultrasound; CI, confidence interval; OR, odds ratio; SE, standard error; US, ultrasound. Diagnostic performance The findings of ROC curve analysis for isthmic location, ill-defined/irregular margin, microcalcifications, peripheral punctate-linear enhancement, and a combined model (isthmic location + ill-defined/irregular margin + microcalcifications + peripheral punctate-linear enhancement) are presented in Table 5 and Figure 6. The DeLong test demonstrated that the combined model achieved the highest AUC (0.944; 95% CI: 0.905–0.984), followed by peripheral punctate-linear enhancement (AUC =0.765; 95% CI: 0.674–0.856), ill-defined/irregular margin (AUC =0.729; 95% CI: 0.628–0.830), isthmic location (AUC =0.702; 95% CI: 0.587–0.816), and microcalcifications (AUC =0.687; 95% CI: 0.572–0.803). The sensitivity and specificity of the combined model were 94.3% and 83.6%, respectively. Table 5Comparison of diagnostic performance in the differentiation of solid thyroid nodules with no or punctate-linear enhancement on CEUSUS and CEUS characteristicsSensitivity (%)Specificity (%)AUC (95% CI)P valueIsthmic location48.691.80.702 (0.587–0.816)0.001*Ill-defined/irregular margin80.065.80.729 (0.628–0.830)<0.001*Microcalcifications45.791.80.687 (0.572–0.803)0.002*Peripheral punctate-linear enhancement91.461.60.765 (0.674–0.856)<0.001*Combined model94.383.60.944 (0.905–0.984)<0.001**, P<0.05. AUC, area under the curve; CEUS, contrast-enhanced ultrasound; CI, confidence interval; US, ultrasound. Comparison of diagnostic performance in the differentiation of solid thyroid nodules with no or punctate-linear enhancement on CEUS *, P<0.05. AUC, area under the curve; CEUS, contrast-enhanced ultrasound; CI, confidence interval; US, ultrasound. Comparison of diagnostic performance between microcalcifications, isthmic location, ill-defined/irregular margin, peripheral punctate-linear enhancement, and the combined model. Discussion This study specifically focused on solid thyroid nodules, which are classified as C-TIRADS 4 or higher according to the 2020 C-TIRADS guidelines, with a malignancy risk ranging from 2% to over 90% (5). Previous studies (8-10) have suggested no or punctate-linear enhancement on CEUS to be a reliable indicator of benign status. However, some studies (11,12) have also reported this pattern being present in malignant cases. This creates a critical clinical dilemma: solid nodules that appear suspicious on US (C-TIRADS 4 or higher) but have a traditionally benign CEUS feature may be incorrectly downgraded to C-TIRADS 2 or 3, which is potentially harmful and may lead to underestimation or missed malignancy. Notably, few previous studies have specifically targeted this high-risk and easily overlooked subgroup. Accordingly, the primary objective of this study was to identify US and CEUS features associated with malignancy in solid nodules with no or punctate-linear enhancement and to thus establish an effective diagnostic approach for this specific subgroup. This may help to avoid misclassification of malignant nodules and reduce unnecessary invasive interventions for benign lesions. Ill-defined/irregular margin, vertical orientation, and microcalcifications are sonographic markers of malignancy (5). In the univariate analysis, these three features were associated with the malignancy of solid thyroid nodules with no or punctate-linear enhancement on CEUS, but only ill-defined/irregular margins and microcalcifications were confirmed to be independent predictors in the multivariate analysis. The loss of independent predictive value for vertical orientation may be attributed, at least in part, to the presence of mummified thyroid nodules (MTNs) in the benign cohort. MTNs arise from the necrosis, desiccation, and subsequent collapse of benign thyroid lesions over time and can display vertical orientation due to the asymmetric fibrous healing associated with transverse shrinking (14). These nodules are characterized by no or punctate-linear enhancement on CEUS (8-10). Although a definitive MTN diagnosis requires imaging evidence of a previously documented benign lesion at the same site (10), we observed that 21 of the 73 benign nodules (28.8%) exhibited the typical feature of MTNs, a double black-and-white halo (10,15). The presence of more than one-quarter of benign nodules with this MTN-like characteristic might have lowered the predictive value of vertical orientation in our study cohort. The location of thyroid nodules has been associated with malignancy risk, with nodules located in the isthmus and upper lobe showing the highest malignant potential (16,17). Although thyroid nodules located in the isthmus were the least common in our study (21.3%), their association with malignancy was the strongest (OR =28.288; 95% CI: 4.515–177.250), which was markedly higher than the OR values reported in previous studies focusing on unselected thyroid nodules (17,18). This difference can be explained by the unique entity examined in our study: solid thyroid nodules showing no or punctate-linear enhancement on CEUS. However, the wide 95% CI surrounding this OR reflects the instability of this estimate due to the limited number of malignant cases in our cohort. Therefore, while isthmic location emerged as a statistically significant predictor, this finding should be interpreted with caution. In clinical practice, isthmic location should not be used alone to evaluate malignancy risk. Instead, it should be evaluated together with the other independent risk factors, including ill-defined/irregular margin, microcalcifications, and peripheral punctate-linear enhancement. The combined predictive model demonstrated robust diagnostic performance (AUC =0.944). In our cohort, the malignancy rate was 73.9% in isthmic nodules and 21.2% in nonisthmic nodules. However, over half of the malignant isthmic nodules were classified in the lower C-TIRADS grades, including three cases of 4A and six cases of 4B. This is likely due to the fact that thyroid nodules tend to grow in the narrow isthmic space and are thus smaller than those in lobes (17,19,20), which may affect the observation of sonographic features. Karatzas et al. found that papillary thyroid carcinomas located in the isthmus were more likely to be associated with lymph node involvement and capsule invasion than those in other thyroid regions (21). Accordingly, greater attention should be paid to the malignant risk of isthmic solid nodules with no or punctate-linear enhancement on CEUS. CEUS allows for the dynamic assessment of microvascular perfusion in thyroid nodules, providing additional diagnostic information for clinical assessment (6,7). The C-TIRADS guidelines proposed by Zhou et al., which outline US malignancy risk stratification for thyroid nodules, recommend that some solid nodules of category 4 or 5 with no or scant punctate-linear enhancement in the whole or most of the regions of the nodules on CEUS can be downgraded to category 2 or 3 (5). However, in our study, some malignant nodules exhibited punctate-linear enhancement, which differs from the well-recognized hypoenhancement, a key CEUS indicator of thyroid malignancy (12,22). This finding suggests that the simple application of this specific CEUS enhancement pattern for downgrading may entail a degree of risk. In our study, the combination of US and CEUS features yielded a robust diagnostic performance for differentiating benign from malignant solid thyroid nodules with no or punctate-linear enhancement, with an AUC of 0.944; this is a value higher than that reported in a previous study (12), which may be due to the differences in study cohorts, with the inclusion of a broader range of enhancement patterns in the previous work. Punctate-linear enhancement pattern, which is an unexpected perfusion pattern for malignant solid nodules, is likely attributable to the heterogeneous microvascular features of malignant nodules. On the one hand, the neovascularization is increased in malignant nodules; on the other hand, the invasive growth of malignant lesions also damages the new blood vessels, forms small tumor thrombi in the necrotic vessels, and results in microvessel occlusion (23). This vascular obstruction disrupts blood flow, induces hypoxic necrosis of internal tissues, and is followed by fibrosis (24). In our study, punctate-linear enhancement was further classified into two subtypes based on the location of microbubble distribution: internal and peripheral patterns. Notably, peripheral punctate-linear enhancement with an ill-defined enhancement margin was the dominant manifestation in malignant nodules. This may be related to the biological nature of thyroid cancer, in which neovascularization often originates at the peripheral area and forms distorted microvessels, appearing as dot-filled microbubbles on CEUS and causing an unclear margin (25). Additionally, no enhancement was exclusively observed in benign nodules, which is consistent with the previous reports (8-10). However, Wu et al. reported a no-enhancement pattern observed in the malignant nodule and speculated that faint infusion—which can be easily missed—might be present within tiny lesions (11). Therefore, further studies with larger sample sizes are needed to confirm the diagnostic value of the no-enhancement pattern for benign solid thyroid nodules. There are several limitations in our study that should be noted. First, selection bias was inevitable due to the retrospective design and the fact that patients without CEUS data or lacking pathological results were excluded. Second, the final diagnosis of benign thyroid nodules involved FNA with at least 6 months of US follow-up as the reference standard, and we did not perform a final histopathological examination to confirm benign status, which might have generated false-negative results. Third, the sample size of our study was relatively small, with a predominance of benign nodules. This imbalance may reduce the statistical power of our analysis, particularly for the evaluation of CEUS enhancement patterns in diagnosing malignant nodules. Thus, further multicenter studies incorporating a greater number of malignant cases and the quantitative analysis of enhancement are needed to validate our findings. Conclusions This retrospective study demonstrated that in solid thyroid nodules with no or punctate-linear enhancement on CEUS, certain sonographic features, including isthmic location, ill-defined/irregular margin, microcalcifications, and peripheral punctate-linear enhancement, are predictors of malignancy. Recognition of these characteristics can facilitate the more accurate differentiation between malignant and benign nodules. Future prospective multicenter studies with larger sample sizes are necessary to validate these findings, and a risk stratification model should be developed to optimize the management of these nodules. Supplementary The article’s supplementary files as Acknowledgments None. Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments, and was approved by the Ethics Committee of China-Japan Friendship Hospital (No. 2019-103-K71). The requirement for informed consent was waived due to the retrospective nature of the analysis. Footnotes Reporting Checklist: The authors have completed the STARD reporting checklist. Available at https://qims.amegroups.com/article/view/10.21037/qims-2025-1-2767/rc Funding: This work was supported by the China-Japan Friendship Hospital Talent Recruitment Project (No. 2019-RC-2). Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://qims.amegroups.com/article/view/10.21037/qims-2025-1-2767/coif). The authors have no conflicts of interest to declare. Data Sharing Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2025-1-2767/dss References Associated Data Supplementary Materials The article’s supplementary files as Data Availability Statement Available at https://qims.amegroups.com/article/view/10.21037/qims-2025-1-2767/dss